Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
Approval Alert | Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Potential Iberdomide Approval May Offer Another Choice in Multiple Myeloma
2
Adding 177Lu-PSMA-617 to ADT Plus ARPI Improves Radiographic PFS in mHSPC
3
CHMP Recommends Pembrolizumab Regimen For Approval in Pretreated PROC
4
Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial
5